Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
LLY · NYSE · United States · Pharmaceutical Preparations
In shortELI LILLY & Co is profitable, generates cash and carries moderate debt, with revenue growing (+44.7% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | – | n/a |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 31.7% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 101.2% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.58× | 65/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.60× | 22/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 25.8% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.81× | 64/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 16.7% | 49/100 |
| Operating margin volatility | – | n/a |
Weight in the score: 20%
| Revenue growth, 3-year average | 31.7% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | 49.3% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 28,318 | 28,541 | 34,124 | 45,043 | 65,179 |
| Cost of revenue | 7,313 | 6,630 | 7,082 | 8,418 | 11,052 |
| Gross profit | 21,006 | 21,912 | 27,042 | 36,625 | 54,127 |
| Research & development | 6,931 | 7,191 | 9,313 | 10,991 | 13,337 |
| Selling, general & admin | 6,432 | 6,440 | 7,404 | 8,594 | 11,094 |
| Interest expense | 340 | 332 | 486 | 781 | 895 |
| Pre-tax income | 6,156 | 6,806 | 6,554 | 12,680 | 25,731 |
| Income tax | 574 | 562 | 1,314 | 2,090 | 5,091 |
| Net income | 5,582 | 6,245 | 5,240 | 10,590 | 20,640 |
| Diluted EPS | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Diluted shares (millions) | 912 | 905 | 903 | 904 | 899 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
Not computed: a required balance-sheet item is missing.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026